Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$1.35 USD
+0.07 (5.47%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.35 0.00 (0.00%) 5:12 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRDL 1.35 +0.07(5.47%)
Will CRDL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDL
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year?
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?
Other News for CRDL
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in ...
Cardiol rises on database lockup for acute myocarditis therapy trial
Cordel Group Chairman Increases Stake in Company
Cordel Group Aligns Executive Incentives with FY25 Bookings Target
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday